BRADLEY WILLIAM purchased $40K of GUTS

BRADLEY WILLIAM purchased 64,516 shares of FRACTYL HEALTH, INC. (GUTS) at $0.62 on 2026-09-14.

Original reporting
SEC EDGAR · BRADLEY WILLIAM
Published Sep 16, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GUTS
Bullish
medium confidence
Mentioned
$GUTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GUTSBullishLow
01

Why it matters

The purchase adds a modest positive data point for GUTS, but the size limits market impact.

02

Market read

Insider purchase is a primary disclosure with modest relevance for GUTS traders.

03

What to watch

Potential upcoming clinical trial data could be the real driver behind the purchase.

Relevance 4/10Novelty 7/10Timing: filed Sep 16 2026 (transaction date Sep 14 2026)

Background

Form 4 filings disclose insider trades; investors watch director purchases for clues on company outlook.

Company-level read

Ticker impact

$GUTSBullishMedium confidence
Context

Director Bradley William purchased 64,516 shares of Fractyl Health (GUTS) for $39,903, indicating insider confidence.

Expected impact

Potential slight upside pressure; limited impact due to small dollar amount.

Evidence & confidence

Form 4 is a primary source; however, $40K is minor for a public float, so price move is likely muted.

Market effects

May signal confidence in biotech pipeline, but limited to Fractyl Health.

No broader regional effect.

Minimal; only relevant to micro‑cap biotech investors.

Counterpoint

Small insider buy could be routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Fractyl Health, Inc.

    Biotech firm listed on NASDAQ under ticker GUTS.

  • Bradley William

    Director of Fractyl Health who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

HighAI 8/10

Fractyl Health (GUTS) Q3 2026 Earnings Call Transcript

Fractyl Health (GUTS) reported Q3 2026 earnings, highlighting positive results from the REMAIN-1 study of its Revita procedure. The study met its 6-month co-primary endpoint with high statistical significance, showing patients maintained 80% of weight loss after stopping tirzepatide. The company plans to submit a de novo marketing application this quarter and expects 12-month data in Q1 2027.

$GUTSMedAI 8/10

Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates

FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita ® participants retained approximately 80% of GLP-1-induced weight loss

$GUTSMed

Fractyl Health receives new U.S. patent for Revita catheter

Fractyl Health (NASDAQ:GUTS) received a new U.S. patent for its Revita catheter and a notice of allowance for a thermal energy control method. The patents extend to 2042 and cover design features and thermal dose delivery. Fractyl plans to submit a De Novo application for Revita, an investigational treatment for post-GLP-1 weight maintenance, which has FDA Breakthrough Device Designation.

$GUTSMed

After weight-loss drugs, Fractyl plans an FDA filing for a procedure to help maintain weight loss.

Fractyl Health (GUTS) announced new patents for its Revita system, aimed at weight maintenance post-GLP-1 therapy. The patents cover the catheter and thermal dosing method, with protection extending to 2042. The company plans an FDA submission for Revita, citing positive REMAIN-1 trial results and patient interest. Fractyl's IP portfolio includes 39 U.S. patents and 50 international patents.

$GUTSHighAI 8/10

Fractyl Health cuts 45% of workforce, focuses on Revita therapy

Fractyl Health (NASDAQ:GUTS) will cut 45% of its workforce to focus on Revita therapy. The company reported positive six-month results for Revita, meeting its co-primary endpoint. Operating cash burn is expected to reduce by 50% to $8M/quarter by Q2 2027. Fractyl plans to submit a De Novo application for Revita in late Q4 2026 and anticipates 12-month data in Q1 2027.

$GUTSMedAI 8/10

A planned 45% workforce cut comes as Fractyl focuses on helping patients keep weight off after stopping weight-loss drugs.

Fractyl Health (GUTS) plans to cut 45% of its workforce, focusing on its lead product Revita. Positive six-month REMAIN-1 trial results were reported, with FDA submission expected in late 2026. The company aims to extend its cash runway into Q2 2027 and reduce quarterly burn by 50%. Development of Rejuva gene therapy will be discontinued, and strategic alternatives will be sought.